Providence Swedish Joins Parkinson's Drug Trial
Seattle's Providence Swedish Neuroscience Institute is the only Washington state site in a 19-site U.S. trial of investigational drug BHV-8000.
Updated on Nov. 17, 2026 in Health

Live Poll
Would you consider joining a clinical trial for an experimental treatment?
Providence Swedish Neuroscience Institute is participating in a clinical trial of BHV-8000, an investigational treatment for Parkinson's disease. It is one of 19 U.S. sites and the only participating site in Washington state.
Why it matters
The trial will test whether BHV-8000 can delay worsening of everyday symptoms in people recently diagnosed with Parkinson's who have not yet started medication. Seattle-area patients gain a local option to take part in the research.
The trial is a double-blind, placebo-controlled study of two BHV-8000 doses in 40-80-year-olds diagnosed within two years, with a 48-week treatment period and up to 13 clinic visits. Whether BHV-8000 delays symptom progression over the roughly one-year measurement window remains unknown.
The players
Providence Swedish Neuroscience Institute
Providence Swedish Neuroscience Institute is a Seattle neurology center within the Providence health system, serving patients across the Puget Sound region.
Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company that sponsors the BHV-8000 trial and develops investigational therapies for neurological conditions.
The details
Participants undergo a screening period of three to eight weeks before entering a 48-week double-blind treatment portion. Those who complete it may be eligible for an optional open-label portion in which all participants receive BHV-8000, and a single follow-up visit occurs four weeks after the last study visit.
Timeline
Screening lasts three to eight weeks before enrollment.
The double-blind treatment portion runs 48 weeks.
The optional open-label portion runs 48 weeks with up to 11 visits.
A final follow-up visit occurs four weeks after the last study visit.
Disease Landscape
BHV-8000 is tested on the premise that brain inflammation driven by microglia may destroy dopamine-producing cells, an approach that departs from treatments that only replace dopamine. The trial's JAK1 and TYK2 blocking mechanism follows a line of anti-inflammatory research that has so far been tested in laboratory studies.
Adults aged 40-80 diagnosed with Parkinson's within the past two years who have not started medication may qualify for screening. Eligible participants would commit to up to 13 clinic visits over 48 weeks plus a follow-up visit.
The takeaway
Patients interested in trial participation should confirm eligibility with the study team, since screening requires three to eight weeks before enrollment. The trial's outcome will show whether targeting brain inflammation can change Parkinson's progression.
Further reading
Explore more on Alzheimer’s research and neurological care.
More information
Find eligibility details on the Biohaven BHV-8000 Parkinson's trial information page.
Source note: This article includes information reported by My Edmonds News.
Live Poll
Would you consider joining a clinical trial for an experimental treatment?






